Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 4/20 | 0.45 |
| ▸ | TTK | P33981 | 8/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.39 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502512 | 0.89 | MAP2K4 (0.41) | MAP2K4TTKMAPK8MAP3K5AURKA | |
| SCHEMBL5381716 | 0.80 | MAP3K5 (0.54) | MAP2K4TTKMAPK8MAP3K5AURKA | |
| SCHEMBL6507804 | 0.79 | TTK (0.43) | MAP2K4TTKMAP3K5AURKAMAPK1 | |
| SCHEMBL6508775 | 0.73 | PIM1 (0.43) | MAP2K4MAP3K5DYRK1APIM1 | |
| SCHEMBL6501695 | 0.72 | MAP3K5 (0.40) | MAP2K4TTKMAPK8MAP3K5AURKA | |
| SCHEMBL5383050 | 0.70 | MAP3K5 (0.51) | MAP2K4TTKMAPK8MAP3K5MAPK1 | |
| SCHEMBL5383228 | 0.70 | MAP3K5 (0.51) | MAP2K4TTKMAPK8MAP3K5AURKA | |
| SCHEMBL5377614 | 0.68 | MAP2K4 (0.62) | MAP2K4TTKMAPK8MAP3K5MAPK1 | |
| SCHEMBL7092069 | 0.68 | PRKAG1 (0.48) | MAP2K4TTKMAPK1MAPKAPK2MAPKAPK3 | |
| SCHEMBL20497344 | 0.67 | AOC3 (0.45) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAP2K4 385/4885TTK 714/4885MAPK8 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.